183 related articles for article (PubMed ID: 17240308)
1. KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate.
Mitsuhashi T; Nakayama M; Sakurai S; Fujimura M; Shimizu Y; Ban S; Ogawa F; Hirose T; Ishihara O; Shimizu M
Ann Diagn Pathol; 2007 Feb; 11(1):49-54. PubMed ID: 17240308
[TBL] [Abstract][Full Text] [Related]
2. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
[TBL] [Abstract][Full Text] [Related]
3. A case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.
Salvatierra A; Tarrats A; Gomez C; Sastre JM; Balaña C
Gynecol Oncol; 2006 Jun; 101(3):545-7. PubMed ID: 16487996
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.
Krug LM; Crapanzano JP; Azzoli CG; Miller VA; Rizvi N; Gomez J; Kris MG; Pizzo B; Tyson L; Dunne M; Heelan RT
Cancer; 2005 May; 103(10):2128-31. PubMed ID: 15812822
[TBL] [Abstract][Full Text] [Related]
5. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcomas.
Do I; Araujo ES; Kalil RK; Bacchini P; Bertoni F; Unni KK; Park YK
Pathol Res Pract; 2007; 203(3):127-34. PubMed ID: 17298867
[TBL] [Abstract][Full Text] [Related]
6. A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH; Kang WK; Bang YJ; Lee KH; Shin DB; Ryoo BY; Roh JK; Kang JH; Lee H; Kim TW; Chang HM; Park JO; Park YS; Kim TY; Kim MK; Lee WK; Kang HJ; Kang YK
Oncology; 2009; 76(5):326-32. PubMed ID: 19307738
[TBL] [Abstract][Full Text] [Related]
7. c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
Miselli FC; Casieri P; Negri T; Orsenigo M; Lagonigro MS; Gronchi A; Fiore M; Casali PG; Bertulli R; Carbone A; Pierotti MA; Tamborini E; Pilotti S
Clin Cancer Res; 2007 Apr; 13(8):2369-77. PubMed ID: 17438095
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment.
Razis E; Selviaridis P; Labropoulos S; Norris JL; Zhu MJ; Song DD; Kalebic T; Torrens M; Kalogera-Fountzila A; Karkavelas G; Karanastasi S; Fletcher JA; Fountzilas G
Clin Cancer Res; 2009 Oct; 15(19):6258-66. PubMed ID: 19789313
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
Chao J; Budd GT; Chu P; Frankel P; Garcia D; Junqueira M; Loera S; Somlo G; Sato J; Chow WA
Anticancer Res; 2010 Feb; 30(2):547-52. PubMed ID: 20332468
[TBL] [Abstract][Full Text] [Related]
11. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas.
Puputti M; Tynninen O; Sihto H; Blom T; Mäenpää H; Isola J; Paetau A; Joensuu H; Nupponen NN
Mol Cancer Res; 2006 Dec; 4(12):927-34. PubMed ID: 17189383
[TBL] [Abstract][Full Text] [Related]
12. Expression study of the target receptor tyrosine kinase of Imatinib mesylate in skull base chordomas.
Orzan F; Terreni MR; Longoni M; Boari N; Mortini P; Doglioni C; Riva P
Oncol Rep; 2007 Jul; 18(1):249-52. PubMed ID: 17549375
[TBL] [Abstract][Full Text] [Related]
13. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
14. Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Koon HB; Bubley GJ; Pantanowitz L; Masiello D; Smith B; Crosby K; Proper J; Weeden W; Miller TE; Chatis P; Egorin MJ; Tahan SR; Dezube BJ
J Clin Oncol; 2005 Feb; 23(5):982-9. PubMed ID: 15572730
[TBL] [Abstract][Full Text] [Related]
15. Inverse correlation of secreted frizzled-related protein 4 and beta-catenin expression in endometrial stromal sarcomas.
Hrzenjak A; Tippl M; Kremser ML; Strohmeier B; Guelly C; Neumeister D; Lax S; Moinfar F; Tabrizi AD; Isadi-Moud N; Zatloukal K; Denk H
J Pathol; 2004 Sep; 204(1):19-27. PubMed ID: 15307134
[TBL] [Abstract][Full Text] [Related]
16. Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors.
de Jong FA; Verweij J
Expert Rev Anticancer Ther; 2003 Dec; 3(6):757-66. PubMed ID: 14686698
[TBL] [Abstract][Full Text] [Related]
17. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
18. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
Sugiura H; Fujiwara Y; Ando M; Kawai A; Ogose A; Ozaki T; Yokoyama R; Hiruma T; Ishii T; Morioka H; Mugishima H
J Orthop Sci; 2010 Sep; 15(5):654-60. PubMed ID: 20953927
[TBL] [Abstract][Full Text] [Related]
20. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
